House Asks FDA To Turn Over Vytorin Study Analysis

NEW YORK (Reuters) - The House Energy and Commerce committee wants the U.S. Food and Drug Administration to turn over the results of an analysis about the potential links between cancer and cholesterol drug Vytorin, the Wall Street Journal reported.

MORE ON THIS TOPIC